Q-omics provides the consensus-scored CHCHD4P4 profile across patient tissues and cancer cell-line models. CHCHD4P4 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CHCHD4P4 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, CHCHD4P4 RNA expression shows 8,324 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, LUSC, and GBM as cancer lineages where CHCHD4P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHCHD4P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHCHD4P4 survival associations across molecular data types. CHCHD4P4 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHCHD4P4 RNA expression–survival associations across cancer types. High CHCHD4P4 expression shows unfavorable associations in UCEC, MESO, LUAD and LUSC, but favorable associations in BLCA and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CHCHD4P4 RNA expression.
This table summarizes CHCHD4P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CHCHD4P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHCHD4P4 shows lower tumor expression in LUSC and HNSC and higher tumor expression in ESCA and BRCA. The LUSC box plot shows higher CHCHD4P4 RNA expression in normal versus tumor tissue (log2 FC = −0.074, t-test p = .014).
This table shows molecular features associated with CHCHD4P4 in patient tissues and cancer cell lines. In patient samples, CHCHD4P4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
